南模生物
(688265)
| 流通市值：13.54亿 | | | 总市值：21.38亿 |
| 流通股本：4938.85万 | | | 总股本：7796.35万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 264,848,483.4 | 176,851,264.77 | 82,932,302.56 | 366,548,781.43 |
| 营业收入 | 264,848,483.4 | 176,851,264.77 | 82,932,302.56 | 366,548,781.43 |
| 二、营业总成本 | 296,662,616.31 | 195,649,343.42 | 99,746,760.11 | 406,101,295.12 |
| 营业成本 | 149,290,455.67 | 98,814,037.62 | 47,016,354.86 | 211,213,022.24 |
| 税金及附加 | 2,202,404.24 | 1,827,354.74 | 880,145.12 | 3,605,268.65 |
| 销售费用 | 45,627,932.27 | 30,150,216.02 | 13,859,227.46 | 51,094,363.52 |
| 管理费用 | 39,826,209.06 | 24,660,099.43 | 17,741,390.5 | 56,422,408.73 |
| 研发费用 | 57,232,634.76 | 38,804,681.16 | 19,334,427.95 | 80,237,407.26 |
| 财务费用 | 2,482,980.31 | 1,392,954.45 | 915,214.22 | 3,528,824.72 |
| 其中:利息费用 | 3,054,903.99 | 2,165,704.27 | 1,076,862.39 | 5,043,355.14 |
| 其中:利息收入 | 1,191,560.45 | -759,110.91 | -189,189.49 | 2,274,074.16 |
| 加:公允价值变动收益 | 15,840,269.92 | 10,434,071.97 | 4,764,766.15 | 759,830.85 |
| 加:投资收益 | 714,176.57 | 714,176.57 | 714,176.57 | 17,250,059.99 |
| 资产处置收益 | -7,835.19 | -7,835.19 | -7,835.19 | -10,923.26 |
| 资产减值损失(新) | -1,332,490.25 | -1,453,100.06 | -1,902,680 | -2,559,865.72 |
| 信用减值损失(新) | -7,741,601.29 | -6,369,088.02 | -880,296.27 | -9,994,761.71 |
| 其他收益 | 3,532,676.1 | 2,361,596.39 | 1,127,723.48 | 4,306,971.07 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -20,808,937.05 | -13,118,256.99 | -12,998,602.81 | -29,801,202.47 |
| 加:营业外收入 | 45,912.99 | 45,912.99 | 45,912.99 | 17,303.73 |
| 减:营业外支出 | 55,474.79 | 55,128.74 | 32,103.88 | 119,680.18 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -20,818,498.85 | -13,127,472.74 | -12,984,793.7 | -29,903,578.92 |
| 减:所得税费用 | -5,623,142.6 | -3,983,899.52 | -87,733 | -9,320,971.87 |
| 六、净利润 | -15,195,356.25 | -9,143,573.22 | -12,897,060.7 | -20,582,607.05 |
| 持续经营净利润 | -15,195,356.25 | -9,143,573.22 | -12,897,060.7 | -20,582,607.05 |
| 归属于母公司股东的净利润 | -15,195,356.25 | -9,143,573.22 | -12,897,060.7 | -20,582,607.05 |
| (一)基本每股收益 | -0.2 | -0.12 | -0.17 | -0.26 |
| (二)稀释每股收益 | -0.2 | -0.12 | -0.17 | -0.26 |
| 八、其他综合收益 | -227,518.56 | 174,186.54 | -91,122.93 | 184,620.33 |
| 归属于母公司股东的其他综合收益 | -227,518.56 | 174,186.54 | -91,122.93 | 184,620.33 |
| 九、综合收益总额 | -15,422,874.81 | -8,969,386.68 | -12,988,183.63 | -20,397,986.72 |
| 归属于母公司股东的综合收益总额 | -15,422,874.81 | -8,969,386.68 | -12,988,183.63 | -20,397,986.72 |
| 公告日期 | 2024-10-31 | 2024-08-29 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |